Damora Therapeutics Inc share price logo

Damora Therapeutics Inc Share Price

NASDAQ: DMRA

$26.39

+0.02

(+0.08%)

as on

Damora Therapeutics Inc Stock Performance

as on March 14, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $25.56
    $27.60
    downward going graph

    3.15%

    Downside

    4.59%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Damora Therapeutics Inc share price movements today

Previous Close
$26.37
Open
$26.79
Volume
297.3K
Day's Low - High
$25.56 - $27.60

Damora Therapeutics Inc Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Damora Therapeutics Inc Stock Fundamentals & Key Indicators

Check Damora Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$-

EPS (TTM)

0

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Damora Therapeutics Inc stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Damora Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
NA$-NANA0.00%

Damora Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Damora Therapeutics Inc Stock has decreased by -6% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-6% versus previous 30 day period

Damora Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
-
-
-
-
-
Gross Profit
-
0
0
0
0
Operating Income
-3
-2
-2
-3
-3
EBITDA
-
-2
-2
-3
-3
Interest Expense
-
-
-
-
-
Depreciation
0
0
0
0
0
Income Before Tax
-3
-6
-2
-3
-3
Income Tax Expense
-
0
0
0
-
Net Income
-3
-6
-2
-3
-3
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%

Damora Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
-
Gross Profit
0
0
0
0
Operating Income
-52
-61
-36
-16
EBITDA
-51
-60
-35
-16
Interest Expense
-
-
-
-
Depreciation
0
0
0
0
Income Before Tax
-51
-61
-38
-21
Income Tax Expense
-
-
-
0
Net Income
-51
-61
-38
-21
Net Profit Margin
0.00%
0.00%
0.00%
0.00%

Damora Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-6
-5
-5
-3
-6
-2
-3
-3
Operating Cash Flow
-11
-5
-4
-3
-4
-2
-2
-2
Investing Cash Flow
9
5
6
-
-
-
-
-
Financing Cash Flow
-
-
-
-
-
-
-
-
Change in Cash
-1
0
1
-3
-4
-2
-2
-2

Damora Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Net Income
-61
-38
-21
Operating Cash Flow
-42
-36
-18
Investing Cash Flow
12
22
11
Financing Cash Flow
0
2
-
Change in Cash
-29
-11
-7

About Damora Therapeutics Inc

Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
OrganisationDamora Therapeutics Inc
HeadquartersOle Maaloes Vej 3, Copenhagen, Denmark, 2200
CEOMs. Lori C. Firmani
E-voting on sharesClick here to vote

Key Management of Damora Therapeutics Inc

Name

Title

Ms. Lori C. Firmani

Chief Financial Officer

Mr. Garrett Winslow Esq.

Senior VP, General Counsel & Corporate Secretary

Mr. Sherwin Sattarzadeh

Interim Principal Executive Officer & COO

Mr. Ulf J. Nilsson Ph.D.

Co-Founder

Dr. Hakon Leffler M.D., Ph.D.

Co-Founder

Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.

Co-Founder

Dr. Becker Hewes M.D.

Chief Medical Officer

FAQs

What is Damora Therapeutics Inc share price today?

Damora Therapeutics Inc share price today is $26.39 as on at the close of the market. Damora Therapeutics Inc share today touched a day high of $27.6 and a low of $25.56.

What is the 52 week high and 52 week low for Damora Therapeutics Inc share?

Damora Therapeutics Inc share touched a 52 week high of $ on and a 52 week low of $ on . Damora Therapeutics Inc stock price today i.e. is closed at $26.39,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

How to invest in Damora Therapeutics Inc Stock (DMRA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Damora Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Damora Therapeutics Inc Shares that will get you 0.0568 shares as per Damora Therapeutics Inc share price of $26.39 per share as on March 14, 2026 at 1:29 am IST.

What is the minimum amount required to buy Damora Therapeutics Inc Stock (DMRA) from India?

Indian investors can start investing in Damora Therapeutics Inc (DMRA) shares with as little as ₹92.409 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹924.09 in Damora Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Damora Therapeutics Inc share’s latest price of $26.39 as on March 14, 2026 at 1:29 am IST, you will get 0.3789 shares of Damora Therapeutics Inc. Learn more about fractional shares .